
Anlon Healthcare Limited IPO
Anlon Healthcare Limited IPO is a Mainboard book building IPO. Price band is ₹91 per share. Minimum investment is ₹14,924. Lot size is 164 shares. Open from 26 Aug 2025 to 29 Aug 2025. Allotment on 1 Sept 2025. Listing on 3 Sept 2025 at BSE, NSE. Managed by Interactive Financial Services Ltd.. Registrar: Kfin Technologies Limited. Key details for GMP, subscription, price, allotment, and listing in one place.
Anlon Healthcare Limited IPO overview
Anlon Healthcare Limited IPO Key figures
Price band, lot, minimum application, and issue window at a glance.
Anlon Healthcare Limited IPO important dates
Anlon Healthcare Limited IPO lot size
| Category | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 164 | ₹14,924 |
| Retail (Max) | 13 | 2,132 | ₹1,94,012 |
| S-HNI (Min) | 14 | 2,296 | ₹2,08,936 |
| S-HNI (UPI) | 33 | 5,412 | ₹4,92,492 |
| S-HNI (Max) | 67 | 10,988 | ₹9,99,908 |
| B-HNI (Min) | 68 | 11,152 | ₹10,14,832 |
About Anlon Healthcare Limited IPO
From the company / RHP narrative.
The company manufactures high-purity pharmaceutical intermediates (for API production) and active pharmaceutical ingredients (used in formulations for medicines, nutraceuticals, personal care, and animal health products).
The company offers pharmaceutical intermediates, APIs for medicines, nutraceuticals, personal care, and veterinary products, all manufactured following Indian and international pharmacopeia standards like IP, BP, EP, JP, and USP.
In addition to manufacturing Pharma Intermediates and APIs to global standards, the company now offers custom manufacturing for complex chemicals, exceeding purity standards and reducing impurities to meet specific customer needs.
The company has received Drug Master File (DMF) approval from ANVISA, NMPA, and PMDA for loxoprofen sodium dihydrate and loxoprofen acid APIs. The company has filed 21 DMFs with global authorities and is in the process of filing for Ketoprofen and Dexketoprofen Trometamol approvals.
The company ensures product quality through rigorous testing, analysis, and process improvements. Supported by four labs, the 34-member team, including 24 science graduates, ensures products meet customer and industry standards.
The company's product portfolio consists of sixty-five (65) commercialised products and twenty-eight (28) products at pilot stage and forty-nine (49) products at laboratory testing stage/ laboratory scale stage.
Products:
Pharma Intermediates:Cyanoethylbe nzoic acid, Ketonitrile and Methyldeslor atadine, these serve as a key starting material or as an advance intermediate for manufacturing of APIs.
Active Pharmaceutical Ingredients: The company’s APIs are key components in pharmaceutical products, delivering therapeutic effects. They are used in formulations like tablets, capsules, ointments, syrups, and in nutraceuticals, personal care, and veterinary products.
Competitive Strengths:
Strong product portfolio and scalable business.
Strong Promoters and Experienced Management Team.
High entry and exit barriers due to long customer approval cycles and strict product standards.
In-house Testing, Quality Control and Quality Assurance for quality control.
Focus on Quality, Environment, Health and Safety.
Objective of the issue
How the issuer plans to use IPO proceeds.
Full or part repayment and/or prepayment of certain outstanding secured borrowingssecured borrowing (term loan)availed by the Company
Funding the working capital requirements of the Company
General corporate purposes
Documents & links
Prospectus, draft filings, and company site open in a new tab.
Registrar
Details about the registrar of the issue.
Issue details
Key details about the issue, including the face value, lot size, and minimum investment.
Related articles
Research posts and updates that reference this company or theme.
Follow IPO & unlisted research in the app, available on iOS and Android.